OpenAI is one of the most valuable private companies in the world, and retail investors keep running into the same wall when they try to own a piece of it. The maker of ChatGPT closed the largest private funding round in history on March 31, 2026, lifting its post-money valuation to $852 billion and leapfrogging SpaceX for the top spot in private markets. There is no OpenAI ticker, no prospectus, and no way to place a standard buy order at your brokerage.

That has not stopped individual investors from finding creative paths to exposure, and a handful of those paths have genuinely opened up over the last six months. Here is what actually works, what only partially works, and where the risks hide.

Why OpenAI Shares Don’t Trade On The Nasdaq

OpenAI is also in no rush to list. CEO Sam Altman has said he is “zero percent excited” about running a public company, and while he has reportedly pushed internally for a Q4 2026 IPO, CFO Sarah Friar believes a 2027 listing is more realistic given the organizational work required. Until then, retail investors have to go sideways.

The Microsoft WorkaroundARK Invest’s Two Doors Into OpenAI

Cathie Wood’s firm opened two different entry points for retail investors in 2026. The primary vehicle is the ARK Venture Fund (ARKVX), a closed-end interval fund that has held OpenAI since 2023 and carries it as roughly 11% of the portfolio, second only to SpaceX at 17%.

The Fundrise Innovation Fund And Its Extreme Premium

VCX has delivered spectacular early gains for holders and a spectacular warning for newcomers. The fund surged more than 590% in its first three trading days, with intraday halts triggered by volatility. At one point it traded more than 1,300% above its net asset value. That extreme premium reflects locked-up supply, because pre-listing shareholders cannot sell for six months after the debut, which has kept the tradable float extremely thin.

Paying a premium of that magnitude means you are not buying OpenAI at an $852 billion valuation, you are buying it at multiples of that implied value. A disciplined approach is to wait for the six-month lockup to roll off, watch the premium compress, and consider entry only when the market price sits closer to the underlying net asset value.

Secondary Markets For Accredited Investors

The practical issues are illiquidity, since you cannot exit on a whim, company approval requirements for most transfers, and the accreditation gate itself, which excludes most retail investors by design.

What To Weigh Before You Commit Capital

Three questions deserve honest answers before you buy any of these vehicles.

First, is the premium worth it? VCX has traded at an extreme markup, and even ARKVX carries meaningful fees. Microsoft, by contrast, trades at a normal forward multiple with OpenAI thrown in. Know what you are paying for the exposure before you click buy.

Second, do you need liquidity? ARKVX only redeems quarterly, with caps. Secondary platforms can tie up capital for years. ETFs and MSFT give you true daily liquidity. The right choice depends on whether this is a satellite position or a meaningful allocation.

Third, what happens if OpenAI never goes public, or lists at a markdown? OpenAI is projected to lose roughly $14 billion in 2026, and its CFO has publicly pushed back on aggressive spending plans. Competition from Anthropic, Google’s Gemini, and well-funded Chinese models is intensifying. A 2027 or later listing is plausible, and a haircut to the $852 billion benchmark is not impossible.

Image credit: Author

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.